drugset
drugset / Trial / NCT06683885

A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

NCT06683885 ↗

Phase 1/2 Recruiting 80 enrolled Mingzhi Zhang
NaSingle-groupOpen-labelTreatment

Summary

A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with newly Diagnosed Diffuse Large B-cell Lymphoma

Timeline

Start
2024-11-20
Primary completion
2026-05-01
Completion
2026-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 10 mg Intravenous
Subject Obutinib Unknown 150 mg Oral
Background Compound Cyclophosphamide Tablets Unknown 50 mg Oral
Background Prednisone Other / unclassified 60 mg Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma